AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Citigroup Downgrades Tandem Diabetes Care to 'Sell' with $14.00 Price Target
ByAinvest
Thursday, Jul 10, 2025 12:53 am ET1min read
Tandem Diabetes Care (TNDM) has been downgraded by Citigroup from "Neutral" to "Sell" with a lower price target of $14.00, a 41.67% decrease. Analysts forecast an average target price of $35.29 with an upside of 112.31% from the current price. The estimated GF Value for TNDM is $46.69, suggesting a 180.93% upside.
Tandem Diabetes Care (NASDAQ:TNDM) experienced a significant drop in its stock price on Wednesday morning following a downgrade by Citi analyst Joanne Wuensch. The stock fell by 5% after being downgraded from "Neutral" to "Sell," with a new price target of $14, a 41.67% decrease from the previous target of $24 [1].The analyst cited intensifying competitive pressures as the primary reason for the downgrade. Wuensch noted that while the 2Q25 delivery will be crucial, competition and the potential impact of competitive bidding are major concerns. She expressed skepticism about Tandem's ability to overcome these challenges in the near term, suggesting that the stock is likely to remain under pressure [1].
Tandem Diabetes Care operates in a market with several established competitors, including Medtronic and Abbott Laboratories. The company manufactures insulin delivery systems for people with diabetes, a sector that has seen increased competition and potential pricing pressures. The analyst's downgrade reflects these competitive pressures and the potential challenges Tandem faces in maintaining its market position [2].
Investors have been cautious about Tandem Diabetes Care's stock, which has been on a continuous losing streak. The stock has fallen by 55.3% since the beginning of the year and is currently trading at $16.01 per share, a significant decrease from its 52-week high of $47.30 [2].
Despite the recent downturn, some investors see the stock market's reaction as an overreaction to the news, indicating that the downgrade may not fundamentally change the market's perception of the business. The estimated GF Value for TNDM is $46.69, suggesting a potential 180.93% upside [2].
References:
[1] https://www.investing.com/news/stock-market-news/tandem-diabetes-stock-falls-after-citi-downgrades-to-sell-on-competition-concerns-93CH-4128112
[2] https://finance.yahoo.com/news/why-tandem-diabetes-tndm-shares-160101666.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet